# Trade Mark Journal No.2026/008 20 February 2026

## UK00004334013 2 February 2026 (5,42)

CYTOSPIRE

Class 5
  Pharmaceutical preparations; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the prevention and treatment of cancer and tumours; pharmaceutical preparations for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; biological preparations for medical purposes; biological preparations for the prevention and treatment of cancer and tumours; biological preparations for use in the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; biological preparations for use in the prevention and treatment of cancer and tumours; biopharmaceuticals for the treatment of cancer; antibodies; diagnostic reagents for medical use.
Class 42
  Scientific and technological services; scientific research; pharmaceutical research and development services; medical research services; drug development services; laboratory analysis; laboratory research; laboratory testing; testing of pharmaceuticals; pharmaceutical research and development services in the field of oncology and immunotherapy; pharmaceutical research and development of pharmaceuticals and drugs for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; medical research services in the field of oncology and immunotherapy; medical research services for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; drug development services in the field of oncology and immunotherapy; drug development services for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; laboratory research and testing of pharmaceuticals in the field of oncology and immunotherapy; laboratory research and testing of pharmaceuticals for the prevention and treatment of oncological disorders, immunological diseases and inflammatory diseases; research and development services in the field of antibodies; research and development in the field of biotechnology; development of antibodies; development of antibodies for use in the field of oncology and immunotherapy; information, consultancy and advice in relation to the aforesaid services.

Cytospire Therapeutics Limited

Representative: CMS Cameron McKenna Nabarro Olswang LLP